CureVac, GSK In Pact To Jointly Develop mRNA Vaccines For COVID-19
February 03, 2021 at 08:28 AM EST
GlaxoSmithKline and CureVac announced a new EUR 150M collaboration to jointly develop next-generation mRNA vaccines for COVID-19 "with the potential for a multi-valent approach to address multiple emerging variants in one vaccine."
